Alexion Pharmaceuticals Inc. Q1 Profit Beats Street on Higher Soliris Sales
Published: Apr 23, 2009
Reuters - Alexion Pharmaceuticals Inc (ALXN.O) posted better-than-expected quarterly earnings as revenue from its genetic-disorder drug Soliris jumped 78 percent.